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Abstract
 
The development of effector and memory CD4 cell populations depends upon both T cell re-
ceptor (TCR) engagement of peptide/major histocompatibility complex (MHC) class II com-
plexes and ligation of costimulatory molecules with counter receptors on antigen-presenting
cells (APCs). We showed previously that sustained interactions with APCs could be crucial for
optimal expansion of CD4 cells and for development of effectors that secrete cytokines associ-
ated with Th2 cells. Using an adoptive transfer model with TCR transgenic CD4 cells, we
now show that responses of CD4 cells primed in B cell–deficient mice become aborted, but are
fully restored upon the transfer of activated B cells. Although B cells have the capacity to se-
crete multiple cytokines that could affect CD4 priming, including IL-4, we were unable to dis-
tinguish a role for cytokines that are secreted by B cells. However, B cell costimulation via the
OX40L/OX40 pathway that has been implicated in CD4 cell expansion, survival, and Th2 de-
velopment was required. Th2 but not Th1 responses were impaired in OX40L-deficient recip-
ients and normal responses were restored with OX40L sufficient B cells. The results suggest
that without engagement of OX40L on B cells, CD4 cell responses to many protein Ag would
be dominated by Th1 cytokines. These data have important implications for strategies to
achieve optimal priming of CD4 subsets.
Key words: CD4 subsets • B lymphocytes • antigen-presenting cells • cytokines • Th2 cells
 
Introduction
 
The development of immunity depends upon the genera-
tion of an expanded population of CD4 effectors which
mediate inflammatory processes that lead to clearance of
foreign Ag and the persistence of a cohort of primed cells
with the capacity to mount a rapid recall response. Initial
activation of naive CD4 cells depends upon prolonged sig-
naling through TCR engagement of peptide/MHC com-
plexes as well as ligation of costimulatory molecules on
APC. Productive interactions can be achieved by sustained
as well as serial encounters of T cells with APC (1). The
duration of stimulation can determine the commitment of
CD4 cells to division which typically correlates with the
development of effector functions (2). Once division com-
mences, effectors can expand and differentiate indepen-
dently of Ag (3, 4). Cytokine production and optimal in-
duction of costimulation are two major mechanisms that
contribute to the growth, differentiation, and survival of
CD4 cells. Through these mechanisms, APCs are integral
not only for initiating a CD4 response but also for deter-
mining magnitude of expansion, and development of effec-
tor populations that secrete cytokines associated with Th1
or Th2 phenotypes (e.g., TNF-
 
 
 
 and IFN-
 
 
 
, or IL-4, IL-5,
and IL-13, respectively). In this context, APCs can be
viewed as orchestrating the outcome of a primary immune
response which determines the frequency of persisting
memory cells and their cytokine commitment.
Naive CD4 cells initially interact with peptide Ag pre-
sented by dendritic cells (DCs)
 
*
 
 which express MHC class
II and B7 family molecules that provide the key costimula-
tion for the induction of the T cell response via CD28 (5).
As a consequence, additional costimulatory receptors are
up-regulated on CD4 cells, including CD40L (CD154),
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Costimulation Requirements for CD4 Cells In Vivo
 
OX40 (CD134), and ICOS (6, 7), and become engaged
with counter-receptors on DC to promote optimal T cell
responses. Once activated, CD4 cells also form conjugates
with B cells (8) which become competent to act as APC
and provide costimulation after activation by uptake of Ag,
ligation of costimulatory/adhesion molecules, or interac-
tion with cytokines. Our previous studies and others have
shown that B cells can be necessary in vivo to support T
cell expansion (9) and in this capacity can play a crucial role
in the development of effector responses and memory (4,
10). We also found that sustained CD4 responses are neces-
sary for the generation of high frequencies of effectors that
secrete the Th2 cytokines, IL-4, IL-5, and IL-13, and that
B cells can function to regulate the processes of differentia-
tion and expansion in vivo (10). Although subsets of DCs
can also promote development of type I or type II CD4
cells (11), recruitment of DCs diminishes after the initial
phase of a response (1), and DCs retain the capacity to
present Ag and produce cytokines that affect T cell differ-
entiation for only a limited duration before further matur-
ing and exiting lymphoid sites (12). Thus, a switch in APC
usage from DCs to B cells can be favored as a response pro-
ceeds, and in many instances may be necessary to sustain
progression to Th2 cytokines.
In this study, we investigated mechanisms that underlie
the capacity of B cells to support CD4 effector develop-
ment in vivo. As our previous work pointed to Ag-inde-
pendent processes, we focused on the involvement of cy-
tokines and costimulation in an adoptive transfer model
where naive TCR transgenic CD4 cells are dependent
upon provision of B cells as APCs for optimal expansion
and differentiation to a Th2 response. Although several
studies suggest that activated B cells produce cytokines that
can regulate DC function as well as T cell survival and ef-
fector development (13, 14), we were unable to distinguish
roles for key cytokines that could participate in this re-
sponse, i.e., IL-4, IL-6, and IL-10. However, costimula-
tion via OX40/OX40L, a TNF/TNFR-family pathway
which regulates CD4 cells (6, 7) was an essential contribu-
tion of B cells.
 
Materials and Methods
 
Mice.
 
Normal and splenectomized C57BL/6, C57BL/6 Igh-6
 
 
 
MT (immunoglobulin 
 
 
 
 chain knock out mice); and B6.PL
Thy1
 
a
 
/Cy, IL-4, -6, and -10 deficient mice were from The Jack-
son Laboratory. OX40L-deficient mice were provided by Dr. B.
Paigen (The Jackson Laboratory, Bar Harbor, ME) with kind
permission from Dr. K. Sugamura (Tohoku University, Sendai,
Japan; reference 15) and bred in our vivarium. OT-II TCR (v
 
 
 
2,
v
 
 
 
5) CD4 transgenic mice that respond to peptide 323–339 of
OVA were obtained from W. Heath (Walter and Eliza Hall, Mel-
bourne, Australia; reference 16) and bred in our colony to
B6.PL-Thy1
 
a
 
/Cy mice to facilitate tracking by Thy 1.1 in
C57BL/6 and 
 
 
 
MT recipients that express Thy 1.2.
 
T and B Cell Isolation and Adoptive Transfer.
 
CD4 cells were
isolated from the spleens and pooled lymph nodes of OT-II Thy
1.1 mice by negative selection using magnetic sorting with an en-
richment cocktail from Stem Cell Technologies Inc. according to
 
the manufacturer’s instructions. V
 
 
 
2, V
 
 
 
5
 
 
 
 cells were quanti-
tated by flow cytometry and 5 
 
 
 
 10
 
6
 
 transgenic CD4 cells were
injected intravenously into C57BL/6, 
 
 
 
MT, or OX40L
 
 
 
/
 
 
 
mice. For some experiments, CD4 cells were labeled before
injection with the fluorescent dye, CFSE (5-and-6)-carboxyfluores-
cein diacetate succinimidyl ester; Molecular Probes). Mice were
immunized on the day of cell transfer by intraperitoneal injection
of 100 
 
 
 
g alum precipitated OVA (Sigma-Aldrich) with 
 
B. pertus-
sis
 
 vaccine organisms (4). In some experiments, mice were also
given a subcutaneous injection of the same dose of Ag at the base
of the tail. B cells were isolated from the spleens of C57BL/6
mice or various knockout mice by magnetic separation with an
enrichment cocktail (Stem Cell Technologies Inc.) and incubated
overnight in RPMI 1640 media (Irvine Scientific) containing 7%
FCS (Irvine Scientific), 200 
 
 
 
g/ml penicillin, 200 U/ml strepto-
mycin, 4 mM 
 
l
 
-glutamine, 10 mM Hepes, and 5 
 
 
 
 10
 
 
 
5
 
 M
2-ME. The cultures were also supplemented with 10 ng/ml rIL-4,
10 
 
 
 
g/ml dextran sulfate (Sigma-Aldrich), 5 
 
 
 
g/ml LPS (Difco
Laboratories), and 100 
 
 
 
g/ml OVA. 5 
 
 
 
 10
 
6
 
 B cells were in-
jected intravenously into T cell recipient mice 24 h after immuni-
zation with OVA.
 
Flow Cytometry.
 
The following reagents from BD Bio-
sciences were used for staining of T and B cells: FITC-conju-
gated rat IgG2a (R35–95), -anti-MHC class II (AF6–120.1),
-CD40 (3/23), and -B7–2 (GL1); PE-conjugated anti-V
 
 
 
2
(B20.1); and biotinyl-anti-V
 
 
 
5 TCR (MR9–4). Peridiunin chlo-
rophyll protein (PerCP)-conjugated streptavidin was from
Becton  Dickinson. APC-conjugated-anti-Thy1.1 (HIS51) and
FITC-conjugated-anti-rat IgG were from eBioscience. FITC-
labeled rat anti-OX40L (RM134L) was a gift from Dr. Michael
Croft (La Jolla Institute of Allergy and Immunology, La Jolla,
CA). Cell division of transgenic cells was analyzed by CFSE
staining after gating on V
 
 
 
2, V
 
 
 
5, and Thy1.1
 
 
 
 cells. Samples
were analyzed with a FACSCalibur™ flow cytometer using
CELLQuest software (Becton Dickinson). 10,000 gated events
were analyzed for surface marker expression and a minimum of
20,000 gated events was collected for CFSE analysis.
 
In Vitro Responses of CD4 Cells.
 
Donor CD4 cells were en-
riched from spleens of recipient mice at various times after cell
transfer as indicated in the text for individual experiments. Anti-
Thy 1.2 labeled magnetic beads (Miltenyi Biotech) were added to
CD4 enrichment mAb from Stem Cell Technologies before
magnetic sorting. Resulting populations of Thy 1.1
 
 
 
 cells were
exclusively transgenic as indicated by v
 
 
 
2 and v
 
 
 
5 expression.
For in vitro restimulation, varying numbers of Thy 1.1
 
 
 
 cells
from individual mice were cultured in triplicate in 250 
 
 
 
l in 96-
well flat-bottomed plates (Costar) with 8 
 
 
 
g/ml OVA peptide,
and with 2 
 
 
 
 10
 
5
 
 APCs that were C57BL/6 spleen cells activated
by overnight culture with dextran sulfate and LPS, and treated
with mitomycin C (4). For limiting dilution analysis (LDA) of
IL-2 and IL-4 secreting cells, serial dilutions of CD4 cells were
plated in 36-well replicates in combination with APC and pep-
tide. For ELISPOT analysis to enumerate IFN-
 
 
 
–producing ef-
fectors, varying numbers of cells were cultured in duplicate with
APCs and peptide for 24 h in Immunospot M200 plates (Cellular
Technology Limited) that were coated with 4 
 
 
 
g/ml anti-IFN-
 
 
 
capture antibody (R46A2 from BD Biosciences).
 
Cytokine Assays.
 
IL-2 and IL-4 secretion were assessed by
bioassay (4). The sensitivity of detection is 1 pg/ml for IL-2 and
0.5 pg/ml for IL-4. For LDA, wells with cpm values greater than
three standard deviations above the mean of values from 36 wells
containing APCs were considered positive. Frequencies were cal-
culated using maximum likelihood analysis. IL-1, -5, -6, -10,T
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-12, -13, and IFN-
 
 
 
 were measured by ELISA as described (10)
using capture and detecting mAb pairs from BD Biosciences. The
sensitivity of detection for these cytokines is 10–30 pg/ml. Re-
combinant cytokines from R&D Systems were used for quantita-
tion. IFN-
 
 
 
 ELISPOTs were developed by sequential incubation
of plates with biotin-anti-IFN-
 
 
 
 (XMG1.2; BD Biosciences),
strepavidin-alkaline phosphatase, and nitroblue tetrazolium/5-
bromo-4-chloro-3-indolyl phosphate substrate (Kirkegaard &
Perry Laboratories) as described (17). ELISPOTs were counted
with an ImmunoSpot Analyzer (Cellular Technology Limited).
 
Results
 
Deficient CD4 Cell Expansion in B Cell–deficient Mice.
 
Our previous studies showed that CD4 cell responses are
suboptimal in B cell–deficient mice as measured by a low
frequency of Ag-specific cells (4) and limited development
of effectors that secrete Th2 cytokines (10). To evaluate
mechanisms that might affect CD4 priming at the level of
Ag-specific CD4 cells, we established an adoptive transfer
model using OT-II v
 
 
 
2, v
 
 
 
5 TCR transgenic CD4 cells
that are specific for OVA. The response of naive transgenic
CD4 cells was followed in C57BL/6 or B cell deficient
(
 
 
 
MT) recipients by flow cytometry after immunization
with OVA protein. An increase in the number of
transgene
 
 
 
 CD4 cells in the spleen was observed by d4 af-
ter immunization (Fig. 1 A). While similar kinetics were
observed with both groups of recipients, a much lower
level of donor cell accumulation occurred in the absence of
B cells. The data suggest that the response of CD4 cells was
not fully supported in 
 
 
 
MT mice and was aborted. To de-
termine if the reduced recovery of OT-II cells reflected
more limited expansion, cell division of transgenic donor
 
cells in recipients was analyzed after CFSE-labeling. OT-II
cells did not begin to proliferate until d3 after immuniza-
tion (Fig. 1 B). Substantially fewer cells divided in 
 
 
 
MT
mice, but division was at the same rate seen in control ani-
mals. By d7, the majority of cells in both groups of recipi-
ents had undergone several divisions, although a larger pro-
portion of the population remains undivided in 
 
 
 
MT mice
(14%) than in C57BL/6 mice (3%). Together the results
suggest that fewer cells become initially committed to divi-
sion in the absence of B cells, and that their expansion is
not sustained.
 
Defective Development of Th2 Cytokine-secreting Effectors in
the Absence of B Cells.
 
Although the capacity of CD4 cells
to produce effector cytokines does not depend upon divi-
sion, several studies indicate DNA synthesis and entry into
cell cycle does typically correlate with effector development,
particularly for secretion of Th2 cytokines (2, 18). Although
our previous study showed limited development of Th2 ef-
fectors in the absence of B cells, we could not directly com-
pare Ag-specific populations from the intact animals (10).
With the adoptive transfer model we could test whether cy-
tokine production by Ag-specific cells was altered as a con-
sequence of priming in 
 
 
 
MT mice. Donor CD4 cells iso-
lated from C57BL/6 and 
 
 
 
MT mice on the basis of Thy1.1
expression on d4 after immunization of recipients were
compared for their capacity to produce IL-2 and several ef-
fector cytokines after restimulation with peptide and APC.
As seen in Fig. 2 A, while OT-II cells produced similar
quantities of IL-2, IL-10, and IFN-
 
 
 
 irrespective of whether
they were primed in normal or B cell–deficient mice, those
from 
 
 
 
MT mice produced markedly lower levels of IL-4
and IL-13. IL-5 was not detectable in this model.
Figure 1. Recovery and division of CD4 cells in im-
munized B cell–deficient mice. (A) 5   106 v 2, v 5
CD4 cells from OTII-Thy1.1 mice were transferred to
Thy1.2  MT or C57BL/6 mice that were then primed
by intraperitoneal injection of 100  g OVA/alum and
B. pertussis organisms. Donor cells in the spleens of re-
cipients were enumerated from the total cell recovery
after FACS® staining with anti-CD4, -Thy1.1, -v 2,
and -v 5. Data are the average values from 2 mice/
group. B. OT-II Thy 1.1  cells were CFSE-labeled
before injection into  MT or C57BL/6 mice that
were primed as for A. Cell division was analyzed as
CFSE fluorescence gating on transgene  donor cells.
Data are representative of three experiments.T
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To determine if limited production of Th2 cytokines re-
flected differences in the levels of secretion by individual
cells and/or the frequencies of cytokine producers, we used
LDA to evaluate IL-2 and IL-4 production by OT-II cells
isolated from recipient mice. As shown in Fig. 2 B, at the
single cell level, OT-II cells produced similar levels of IL-2
and IL-4/cell whether primed in normal or 
 
 
 
MT mice.
The frequencies of IL-2–producing cells were similar in
both groups of recipients, but fivefold fewer IL-4 produc-
ers were detected among OT-II cells from 
 
 
 
MT mice.
These data establish that cells with the capacity to produce
normal levels of IL-4 do develop in the absence of B cells,
but that fewer cells are present in the effector populations
from 
 
 
 
MT mice.
 
Activated B Cells Restore CD4 Cell Responses in 
 
 
 
MT
Mice.
 
Our studies showed that splenic DC from 
 
 
 
MT
mice are not defective in their ability to initiate or support
CD4 cell responses but are likely to become limiting (4,
10). To confirm that B cells can be responsible for deficient
priming of CD4 effectors, C57BL/6 and 
 
 
 
MT mice were
reconstituted with activated, Ag-pulsed B cells. Provision
of B cells fully restored expansion of OT-II cells in 
 
 
 
MT
mice (Fig. 3 A) as well as the capacity for Th2 cytokine se-
cretion (Fig. 3 B). We showed previously that transferred B
cells persisted throughout CD4 effector development in
 
 
 
MT mice (10) and here we find that the optimal time pe-
riod for reconstitution of the response was during the initial
48 h (Fig. 3 C). While the numbers of IL-4–producing
cells were augmented by the presence of B cells in 
 
 
 
MT
mice, frequencies of IFN-
 
 
 
–producing effectors were not
significantly altered (Fig. 3 D), as we showed previously for
innate CD4 cells from 
 
 
 
MT mice (10). The results suggest
that the IFN-
 
 
 
 response which can develop before that of
IL-4 (2, 19) can be optimally primed without a contribu-
tion from B cells.
 
Limited CD4 Responses in 
 
 
 
MT Mice Are Not Restricted to
the Spleen.
 
A previous study showed that B cell–deficient
mice have reduced numbers of T cells and DCs in their
spleens as well as defective splenic T zone architecture due
to the absence of B cells during development (20). Although
we find that OT-II cells localize normally in the spleens of
 
 
 
MT mice (unpublished data), their limited accumulation/
expansion after priming might reflect not only limited avail-
ability of APC, but also defects in the microenvironment
that include reduced numbers of stromal cells and expression
of the lymphoid tissue chemokine, CCL21. However, T
zone development as well as chemokine expression in LN is
B cell independent and 
 
 
 
MT mice have normal T cell and
DC numbers in these tissues. Thus, if B cells directly rather
than indirectly contribute to CD4 effector responses, their
requirement should also be evident in the LN.
To test this hypothesis, C57BL/6 or 
 
 
 
MT recipients
were injected with CFSE-labeled OT-II cells and immu-
nized with OVA and adjuvant (subcutaneously and intra-
peritoneally). An additional group of 
 
 
 
MT recipients also
received activated B cells. Division of the transgenic donor
cells was assessed in LN at 2 1/2 d after priming. Fewer
transgene
 
 
 
 cells were dividing at this time in 
 
 
 
MT mice
than in C57BL/6 mice, and the presence of B cells im-
proved both expansion (Fig. 4 A) and recovery (Fig. 4 B).
The data suggest that, as previously observed in studies
mice rendered B cell deficient by antibody treatment (21),
B cells are necessary for CD4 cell responses in LN as well as
spleen. To determine if migrating cells from the spleen
might contribute to the defective response in LN, we also
evaluated cytokine secretion of OT-II cells primed in sple-
Figure 2. Defective development of Th2 cytokines in the absence of B cells. (A) Transgene  OT-II Thy 1.1 cells were transferred to  MT or C57BL/6
mice that were immunized as for Fig. 1. On d4, donor cells were enriched from recipient spleens by magnetic sorting and cultured with APCs and OVA
peptide. Culture supernatants were tested at 36h by bioassay for IL-2 and IL-4, or by ELISA for IL-10, IL-13, and IFN- . Data are the average cytokine
amounts in cultures of 5   104 (IL-4 and IL-13) or 2.5   104 transgene  cells/well (other cytokines). (B) v 2, v 5, Thy 1.1 cells that were recovered on
d4 from  MT or C57BL/6 OVA-primed mice were serially diluted in 36-well replicate cultures containing APC and OVA peptide. Supernatants were
tested for IL-2 and IL-4. At the dilution where IL-2 or IL-4 producers/well is limiting (i.e.,  37% negative wells), the average amount of IL-2 or IL-4 per
well of replicate cultures that scored positive is shown. Frequencies (shown above each bar) were quantitated using maximum likelihood analysis.T
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nectomized recipients. As shown in Fig. 4 C, a more lim-
ited Th2 cytokine response was seen in  MT mice unless
reconstituted with B cells, and there were no differences
relative to the controls.
B Cell–derived Cytokines Do Not Have an Apparent Role in
Sustaining CD4 Responses. One mechanism by which B
cells could contribute to Th2 differentiation is through cy-
tokine production. We found that B cells that were acti-
vated in culture produced readily detectable levels of sev-
eral cytokines that included IL-1, -2, -4, -6, -10, and -13,
as well as IFN-  (Fig. 5 A). In view of a major role for IL-4
in CD4 cell differentiation, and a potential in vivo role for
B cell-derived IL-4 in Th2 development (13, 22), we iso-
lated B cells from IL-4 knockout mice and assessed their
Figure 3. Activated B cells restore CD4 cell expansion
and Th2 cytokine secretion. (A) Two groups of  MT
mice and 1 group of C57BL/6 mice were injected with
OT-II Thy 1.1 cells and primed intraperitoneally with
OVA/adjuvant as for Fig. 1. After 24 h, 1 group of  MT
hosts was injected with 5   106 B cells that were activated
as indicated in the Material and Methods. On d4 after
priming, transgene  cells were enumerated as for Fig. 1.
(B) Using the same groups as in panel A, IL-4 and IL-13
production by v 2, v 5 CD4 cells isolated 4 d after prim-
ing was measured at 36 h after restimulation with APC and
OVA peptide. (C) OT-II Thy 1.1 cells were transferred to
four groups of  MT mice and one group of C57BL/6
mice that were subsequently primed intraperitoneally with
OVA/adjuvant. Activated B cells were injected into each
of three groups of  MT mice 1, 2, or 3 d after receiving
CD4 cells. On d4 after priming, 5.0   104 transgene 
cells/well were tested for IL-4 or IL-13 secretion after re-
stimulation with APC and OVA peptide. (D) IL-4 and
IFN-  producing cells in C57BL/6,  MT, and B cell–
reconstituted  MT mice were enumerated by LDA and
ELISPOT assay, respectively. The data shown for panels
A–D are the average responses of three mice/group.
Figure 4. Defective CD4 cell response is not
limited to the spleen. (A) Transgene  OT-II Thy
1.1 cells were CFSE-labeled before injection into
one group of C57BL/6 mice or two groups of
 MT. At the time of cell transfer, recipients were
immunized subcutaneously and intraperitoneally
with OVA/adjuvant. One group of  MT mice was
injected with B cells on the day after priming as for
Fig. 3. At 60 h after cell transfer, cell division of do-
nor cells in draining periaortic and mesenteric
lymph nodes was analyzed by CFSE fluorescence of
transgene  cells. (B) Recovery of transgene  cells
determined from the total cell counts for the three
groups of recipients shown in panel A on d4 after
cell transfer. Data are representative of two experi-
ments. (C) Responses of transgene  cells from
lymph nodes of normal and splenectomized  MT
and C57BL/6 recipients on d4 after cell transfer
and intraperitoneal and subcutaneous immunization
with OVA/adjuvant as for panel A. Additional control and splenectomized  MT recipients were injected with B cells as for Fig. 3. IL-13 secretion by
5   104 donor transgene  cells was assessed after restimulation with APC and OVA peptide.T
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capacity to restore responses of  MT mice. We also exam-
ined B cells from IL-6–deficient mice, since this cytokine
can support differentiation and survival of Th2 cells (23)
and IL-10–deficient mice, as IL-10–mediated down-regu-
lation of IL-12 synthesis by DCs can facilitate Th2 re-
sponses (24). However, B cells from the cytokine-deficient
animals were fully capable of restoring development of IL-
13–producing effectors in  MT mice (Fig. 5 B). The levels
of IL-4 secretion were also normal when  MT mice were
reconstituted by B cells from the cytokine deficient animals
(unpublished data). The data suggest either that redun-
dancy of cytokine functions can compensate for a single
deficiency, or that B cell production of IL-4, -6, or -10 is
not obligatory.
A Role for Costimulation via B Cell Expression of OX40L in
Sustaining CD4 Responses. Like DC, activated B cells ex-
press multiple costimulatory molecules that are involved in
the development of CD4 responses as revealed by the dra-
matic consequences of gene knockout studies (5, 7, 15, 25).
However, activated T cells are less dependent upon co-
stimulation. It is unclear whether continued availability is
necessary once a response is underway when cytokines that
can drive expansion and survival become produced in the
local milieu. The OX40L/OX40 pathway that has been
implicated in both T cell priming and T–B interactions
(26–28) appears to also have the potential to contribute to
effector responses in vivo (15, 29). We therefore deter-
mined if this pathway might play a role in B cell regulation
of CD4 effector development in our model. We used B
cells from the OX40L gene knockout animals (15) to re-
constitute OT-II responses in  MT mice. These B cells
expressed normal levels of class II MHC, as well as B7–2,
and CD40 (Fig. 6 A). However, activated B cells that
lacked OX40L were incapable of restoring the IL-4 and
IL-13 responses whereas IFN-  responses were normal in
the absence of B cells and not further augmented by their
addition (Fig. 6 B).
It is noteworthy that CD4 cell proliferation is defective
in mice that lack OX40 (30), suggesting that a major con-
tribution of costimulation through this pathway is to pro-
mote T cell expansion. OX40 deficient CD4 cells have
been shown to become initially activated to secrete IL-2
and divide normally, but they are unable to sustain prolifer-
ation (29). As OX40L deficient mice have normal numbers
of T and B cells, we asked whether OX40L signals from B
cells affect the development of Th2 responses. OT-II cells
were transferred into C57BL/6 or OX40L /  mice and
primed with OVA protein/adjuvant. An additional group
of OX40L /  recipients were then given C57BL/6 B cells
as in the experiments with  MT mice. On d4 after immu-
nization, the cytokine responses of reisolated transgenic do-
nor cells were measured. As shown in Fig. 7, OT-II cells
primed in OX40L /  mice were defective in their produc-
tion of IL-4 and IL-13 but not of IFN-  or IL-2 (unpub-
lished data). Importantly, B cells from normal mice fully
restored defective Th2 priming in OX40L /  recipients.
Together with the experiments showing that OX40L /  B
cells do not restore the responses of  MT mice, the data
reveal that OX40L expression on B cells can be crucial for
the expansion/survival of Th2 cells.
Discussion
Many studies indicate that B cell and T cell responses are
coordinated to orchestrate cross regulation of expansion,
survival, and differentiation via cooperative interactions.
Although the essential role of CD4 cell–derived cytokines
in B cell differentiation and responses has been widely stud-
ied, mechanisms that underlie the regulation of CD4 cell
responses by B cells have not yet been fully explored. In
this study, we determined that B cells can directly affect
CD4 effector responses through costimulation by OX40L.
We show that in the absence of B cells that express
OX40L, Ag-induced expansion of CD4 cells and develop-
ment of effectors that secrete Th2 cytokines are impaired.
Several studies have identified a link between B cell Ag-
presentation and the induction of IL-4 secretion by CD4
cells (31, 32) but did not reveal whether additional signal-
ing pathways were required. Although a recent report sug-
gests that B cells can provide a source of IL-4 for differenti-
ation of Th2 cells (13), this does not appear to be the sole
Figure 5. Role of cytokine secretion by B cells. (A) Purified B cells
were cultured at 2   106/ml with 10  g/ml dextran sulfate, 5  g/ml
LPS, and 100  g/ml OVA. Supernatants collected at 24 h were tested for
IL-2, -4, -1, -6, -10, -12, -13, and IFN- . The average pg/ml from five
separate experiments is shown for each cytokine. (B) B cells purified from
C57BL/6 (control), IL-4 / , IL-6 / , and IL-10 /  mice were activated
and transferred to  MT mice that were injected 24 h previously with
OT-II Thy 1.1 cells and immunized intraperitoneally with OVA/adju-
vant as for Fig. 1. On d4 after priming, v 2, v 5, Thy 1.1 cells were iso-
lated and 5   104 tested for IL-13 secretion by comparison to transgene 
cells recovered from C57BL/6 mice and from  MT mice that did not re-
ceive B cells. Shown are the average responses of 3–5 mice/group nor-
malized to the response by OT-II cells immunized in C57BL/6 mice.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
881 Linton et al.
mechanism to support Th2 responses since our results show
that IL-4–deficient B cells were fully capable of eliciting
Th2 cytokines. However, it is striking that several costimu-
lation molecules have profound effects on the development
of CD4 cells. It has been proposed that three major costim-
ulatory pathways, CD28/B7, CD40L/CD40, and OX40/
OX40L, act sequentially and synergistically to regulate
CD4 cell responses from initial activation to optimal ex-
pansion, survival, and migration into B cell follicles (6). Al-
though CD4 cell signaling through CD28, CD40L, or
OX40 are associated with IL-4 induction (6), in vivo stud-
ies suggest that IL-4 production and responses that require
IL-4 may be particularly dependent upon the OX40/
OX40L pathway (27, 33, 34). Our data reveal that B cells
can be an essential population to provide signals via
OX40L to CD4 cells.
We envision that following CD4 cell activation by
TCR-interactions with MHC/peptide complexes and
CD28 engagement of B7 molecules, receptors such as
CD40L and OX40 are induced and serve to amplify TCR
signaling, as well as enable responding T cells to interact
with B cells which constitutively express CD40 and up-
regulate OX40L in response to activation. Temporally,
OX40 expression on T cells coincides with induction of
OX40L on B cells (27). Although interactions with DCs
can initially support the response, they become limiting as
T cells proliferate, and without further recruitment of DC,
usage of B cells can become necessary to sustain the re-
sponse. Our data suggest that CD4 cells can be maintained
in this physiologic context by OX40 interactions with
OX40L on B cells. Although this pathway can also contrib-
ute to the early activation phase of CD4 responses via DCs
(15), our study of the knockout animals as recipients of Ag-
specific CD4 cells shows that although priming occurs,
Th2 responses are limited. Importantly, normal B cells are
sufficient to restore Th2 effector development.
Our previous studies suggest that other APC can fulfill
the role of B cells in CD4 cell expansion and Th2 develop-
ment if made available in sufficient numbers during effector
priming (4, 10). In addition, provision of costimulation to
T cells via signaling with an agonist antibody to OX40 (29)
is associated with increased frequencies of Ag-specific CD4
cells. Recent studies also implicate OX40 in survival of ac-
tivated CD4 cells (35), suggesting that expansion together
Figure 6. A role for OX40L expres-
sion on B cells in sustaining CD4 re-
sponses. (A) Purified B cells from groups
of two OX40L /  or C57BL/6 mice
were cultured 64 h with 10 ng/ml rIL-4,
10  g/ml dextran sulfate, 5  g/ml LPS,
and 100  g/ml OVA before staining and
FACS® analysis. Shown as solid histo-
grams is fluorescence staining for class II
MHC, CD40, CD86 (B7–2), and
OX40L compared with isotype controls
(open histograms). Data are representative
of 2 experiments. B. B cells purified from
C57BL/6 (control B cells) or OX40L / 
mice were activated and transferred to
 MT mice that were previously injected
with OT-II Thy 1.1 cells and immunized
with OVA/adjuvant as for Fig. 1. Con-
trol C57BL/6 and  MT mice did not re-
ceive B cells. On d4 after priming, v 2,
v 5 cells were isolated and tested for
IL-4, IL-13, and IFN-  secretion as for
Fig. 2. Shown are cytokine levels de-
tected from 2–6 mice per group. The data
are representative of four experiments.
Figure 7. OX40L deficiency
in B cells is sufficient to limit
Th2 development. C57BL/6
mice and two groups of
OX40L /  mice were injected
with OT-II Thy 1.1 cells and
immunized intraperitoneally
with OVA/adjuvant. B cells
from C57BL/6 mice were acti-
vated and transferred to one
group of OX40L /   recipients
on the day after T cell transfer. Control C57BL/6 and OX40L /  mice did not receive B cells. On d4 after priming, transgene  donor cells were iso-
lated and tested for IL-4, IL-13, and IFN-  secretion as for Fig. 2. Shown are cytokine levels detected from 2–4 mice per group. The data are represen-
tative of two experiments.T
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with increased lifespan may allow effectors to participate in
a response for an extended period. Our results where a
high number of Ag-specific naive CD4 cells are present at
the time of immunization show that the capacity to secrete
several effector cytokines, with the notable exception of
Th2 cytokines, can develop independently of expansion
that is sustained via OX40/OX40L interactions.
In view of our finding that IL-4 producing effectors,
though reduced in number appear to be primed normally,
and previous reports that OX40/OX40L interactions
maintain later rather than initial CD4 cell expansion, we
envision an indirect role of costimulation in the develop-
ment of Th2 responses through effects on survival (35) and
division (29). The data support the concept that sustained
responses are necessary for optimal Th2 development (19).
As the OX40 pathway has been associated with CD4 cell
accumulation in germinal centers (36), it is attractive to
speculate that B cell regulation of CD4 cell survival and re-
sponse by OX40 in turn facilitates a sustained B cell re-
sponse (37). Although cytokines produced by APC includ-
ing IL-13, IL-1, and IL-6 can support Th2 differentiation,
IL-4 is the key mediator to function in this capacity (38).
The lag in optimal priming for IL-4 synthesis in our model
may in part be due to dependence of responding CD4 cells
upon autocrine secretion and usage of IL-4 to direct Th2
development (39) through induction of transcription fac-
tors that include Stat6, Gata3, and Gfl-1 (38, 40). Condi-
tions of strong TCR stimulation and costimulation may be
necessary to achieve sufficient endogenous IL-4 levels for
commitment to a Th2 phenotype and achieve stable secre-
tion after extended chromatin remodeling that accompa-
nies cell division (41).
Our study shows that in vivo, OX40L expressed on B
cells can play a crucial role in determining the outcome of a
response in terms of the frequency and cytokine commit-
ment of effectors and, from our previous work and that of
others, in turn on persisting memory. In the absence of B
cell involvement, CD4 cell responses, at least to many pro-
tein Ag would most typically be biased toward Th1 cyto-
kines, as is often observed in responses where Ag is limiting
or of low affinity. The data indicate that modulation of co-
stimulation through OX40 can provide a key checkpoint
in the regulation of CD4 cell responses.
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